The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Are The Forecasted Market Size Figures For The Sterile Injectables CDMO Market In 2026 And 2030?
The sterile injectables cdmo market size has seen rapid growth in recent years. It is anticipated to expand from $6.65 billion in 2025 to $7.36 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.7%. The historical expansion of this market can be attributed to several factors, including insufficient cdmo infrastructure for sterile injectables, a rising demand for small molecule injectables, a reliance on in-house formulation development, increased regulatory scrutiny concerning sterile manufacturing processes, and an overall increase in global pharmaceutical production.
The sterile injectables CDMO market size is projected to undergo rapid expansion over the next few years. It is expected to grow to $10.91 billion in 2030, achieving a compound annual growth rate (CAGR) of 10.3%. This anticipated growth during the forecast period can be attributed to the increasing scale of large molecule biologics manufacturing, a rising demand for cell and gene therapies, the adoption of advanced aseptic processing technologies, an increase in outsourcing activities to CDMOs, and the growing needs for specialized packaging and cold chain storage. Key trends for the forecast period include an elevated demand for contract manufacturing of sterile injectables, the expansion of analytical and testing services to ensure quality, an increase in the production of monoclonal antibodies, peptides, and cell/gene therapies, greater utilization of lyophilized, emulsion, and reconstitutable injectable formats, and the integration of formulation development with packaging and storage solutions.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25912&type=smp
What Influential Factors Are Boosting The Sterile Injectables CDMO Market Demand?
The escalating demand for biologics and biosimilars is anticipated to boost the expansion of the sterile injectables CDMO market. Biologics are medications derived from living cells or organisms, specifically designed to target particular disease elements, while biosimilars are almost exact replicas of approved biologics, mirroring their quality, safety, and effectiveness. This growing demand stems from an increasing occurrence of chronic and complex health issues, as these novel therapies provide more focused and efficacious treatment options compared to conventional drugs. Consequently, the need for biologics and biosimilars leads to greater dependence on sterile injectable CDMO services, given that these treatments are frequently administered by injection and necessitate meticulously controlled sterile environments to guarantee safety, quality, and compliance with regulations. For example, data from February 2025, provided by the Center for Biosimilars, a US-based nonprofit research organization, indicated that the US allocated an estimated US $324 billion to biologic medicines in 2023, accounting for approximately 45% of the country’s total prescription drug spending. Thus, the escalating demand for biologics and biosimilars is a key factor propelling the expansion of the sterile injectables CDMO market.
How Is Segment Classification Applied In The Sterile Injectables CDMO Market?
The sterile injectables cdmo market covered in this report is segmented –
1) By Type: Small Molecule, Large Molecule
2) By Service: Formulation Development, Analytical And Testing Services, Manufacturing, Packaging, Storage, Other Services
3) By Route Of Administration: Subcutaneous (SC), Intravenous (IV), Intramuscular (IM), Other Routes Of Administration
4) By Therapeutic Area: Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Disorders, Musculoskeletal Diseases, Hormonal Diseases, Other Therapeutic Areas
5) By End-User: Pharmaceutical Companies, Biopharmaceutical Companies, Research Institutes, Other End-Users
Subsegments:
1) By Small Molecule: Solutions, Suspensions, Lyophilized Injectables, Emulsions, Reconstitutable Powders
2) By Large Molecule: Monoclonal Antibodies (mAbs), Peptides And Proteins, Vaccines, Cell And Gene Therapies, Insulins And Biosimilars
What Trends Are Influencing The Sterile Injectables CDMO Market Outlook?
Leading firms within the Sterile Injectables CDMO market are prioritizing the creation of novel solutions, including modular aseptic filling platforms, with the aim of improving adaptability and productivity in sterile drug manufacturing. These modular aseptic filling platforms represent adaptable isolator-based sterile filling systems constructed from interchangeable components, empowering CDMOs to swiftly transition between vial, syringe, or cartridge formats. This capability aids in shortening changeover periods, reducing product wastage, and effectively accommodating small- to mid-scale batches intended for clinical and commercial sterile injectables. As an illustration, in February 2025, Recipharm AB, a contract development and manufacturing organization (CDMO) based in Sweden, introduced a fully functional modular sterile filling system at its Wasserburg, Germany site. This system is specifically designed for the aseptic filling of small to mid-scale batches (500–50,000 units). This particular line minimizes product loss (less than 500 milliliters), accommodates interchangeable filling modules, and facilitates the efficient processing of high-value biologics inside a fully enclosed isolator.
Who Are The Firms Contributing To The Sterile Injectables CDMO Market Ecosystem?
Major companies operating in the sterile injectables cdmo market are Pfizer Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim, Fresenius Kabi AG, Lonza Group Ltd., Catalent Inc., Samsung Biologics Co. Ltd., Fareva SA, Recipharm AB, PCI Pharma Services, Vetter Pharma, Delpharm, Kindeva Drug Delivery LP, Ajinomoto Bio-Pharma Services, Cenexi, Grand River Aseptic Manufacturing Inc., INCOG BioPharma Services, Aurigene Pharmaceutical Services, Jubilant HollisterStier LLC, Symbiosis Pharmaceutical Services Ltd., Afton Scientific Corp., Amaran Biotechnology Inc.
Access The Complete Sterile Injectables CDMO Market Report:
https://www.thebusinessresearchcompany.com/report/sterile-injectables-cdmo-global-market-report
Which Region Contributes The Most To The Sterile Injectables CDMO Market?
North America was the largest region in the sterile injectables CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sterile injectables cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Sterile Injectables CDMO Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=25912&type=smp
Browse Through More Reports Similar to the Global Sterile Injectables CDMO Market 2026, By The Business Research Company
Generic Oncology Sterile Injectable Market Report 2026
Injectable Drug Delivery Devices Market Report 2026
Sterile Medical Packaging Market Report 2026
https://www.thebusinessresearchcompany.com/report/sterile-medical-packaging-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model